# Nuclide record nct03533283 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct03533283/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct03533283", "NCT03533283" ;
  schema:name "An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma"@en ;
  schema:description "A phase 1/2 trial of Glofitamab, Atezolizumab, Obinutuzumab, Tocilizumab and Polatuzumab vedotin in hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct03533283/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03533283> ;
  nuclide:status "active" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:related <https://nuclide.cc/isotopes/zr-89/> .